Licensing · MENA · Announced 26 Dec 2022
Shanghai Junshi Biosciences → Hikma Pharmaceuticals
Licensing deal between Shanghai Junshi Biosciences (China) and Hikma Pharmaceuticals (Jordan), covering Toripalimab, announced 26 Dec 2022.
Parties: Shanghai Junshi Biosciences (China) → Hikma Pharmaceuticals (Jordan)
- Deal type
- Licensing
- Value
- See terms
- Territory
- MENA (all Hikma markets)
- Therapeutic area
- Oncology
- Asset
- Toripalimab — anti-PD-1 monoclonal antibody (immune checkpoint inhibitor)
- Announced
- 26 Dec 2022
Our analysis
Why it matters
The founding node of the China→MENA innovation corridor. This is one of the earliest and most significant expressions of the pattern our tracker keeps surfacing: a Chinese innovator owns the science, a MENA champion supplies the regulatory, commercial and distribution reach.
Junshi explicitly framed toripalimab as potentially the first marketed Chinese anti-PD-1 antibody in MENA — a genuine first.
The full analysis is free to read with a work email on this page.
Source: Financial Post